Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

28.54
+0.16000.56%
Pre-market: 28.34-0.2007-0.70%09:05 EDT
Volume:5.41M
Turnover:154.84M
Market Cap:3.60B
PE:-6.11
High:29.06
Open:28.39
Low:28.12
Close:28.38
52wk High:43.15
52wk Low:25.77
Shares:126.00M
Float Shares:123.00M
Volume Ratio:0.81
T/O Rate:4.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.81
PE(LYR):-8.94

Loading ...

Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

THOMSON REUTERS
·
Sep 22

Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo

THOMSON REUTERS
·
Sep 22

Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since September 2023

Dow Jones
·
Sep 22

Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market

Bellwether Stocks Movement
·
Sep 15

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Sep 14

GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market

Options & Short Sell
·
Sep 14

Viking Therapeutics to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Der Aktionaer editor speculates on timing of Viking Therapeutics data

TIPRANKS
·
Aug 25

Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In

Simply Wall St.
·
Aug 20

Viking Therapeutics Director Dorothy Elizabeth Kelly-Gemmell Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Viking Therapeutics Posts Corporate Presentation Outlining Obesity Drug Pipeline Led by Vk2735 Phase 3 Program

Reuters
·
Aug 06

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live
·
Aug 04

Oppenheimer says VK2735’s options create compelling reason to own Viking

TIPRANKS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), AbbVie (ABBV) and Cencora (COR)

TIPRANKS
·
Aug 01

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

MT Newswires Live
·
Jul 31

Viking Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 31

Viking Therapeutics (VKTX) Receives a Buy from Jefferies

TIPRANKS
·
Jul 30